At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 156 enrolled
Drug / intervention
Pioglitazone +1 moredrug
Likely dose
Pioglitazone 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Pioglitazone Compared to Placebo on Bone Metabolism in Impaired Fasting Glucose, Postmenopausal Women for One Year of Treatment
In Brief
A Phase 4 clinical trial evaluating Pioglitazone and Placebo for Bone Metabolism. Completed, enrolled 156 participants across 34 sites.
Detailed Summary
The purpose of this study is to evaluate the effect of pioglitazone on bone metabolism in postmenopausal women with impaired fasting glucose.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBone Metabolism
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedJul 2008
Primary CompletionJan 2011
Study CompletionFeb 2011
TodayJul 2026
First PostedJul 2, 2008
Enrollment StartMay 1, 2008
Primary CompletionJan 1, 2011
Study CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 18 years ago
Interventions
Pioglitazonedrug
Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.
Placebodrug
Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.